Anti-CD20 Antibody-Cytokine Fusion Protein, IgG (Rituximab)-IL2
Cat. No: ACFP-SH132

PRODUCT INFORMATION

Product Overview
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD20 as well as the biological activity of IL2. Antibody-cytokine fusion protein has a number of useful biological properties, including the ability to bind human B-cells; the ability to bind to CD20 antigen; a reduced ability to elicit an immune response in a human patient; and activity against B cell proliferative disorders such as leukemias, lymphomas, rheumatoid arthritis, and other autoimmune diseases. This immunocytokine was designed for treating leukemias, lymphomas, rheumatoid arthritis, and other autoimmune diseases.

Target
CD20
Molecule Class
L Kappa; IgG1-IL2
Species Reactivity
Human
Host
Chimeric (Human-Mouse)
Expression Host
CHO
Related Disease
Leukemias, Lymphomas, Rheumatoid arthritis, and other autoimmune diseases
Cytokine 1
IL2
Cytokine 1 Species
Human
Cytokines 1 Description
Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.

Applications
This product can be used therapeutically to deliver biologically active ligands to a desired tissue.

TARGET INFORMATION

Alternative Names
MS4A1; membrane-spanning 4-domains; subfamily A; member 1; B1; S7; Bp35; CD20; CVIDS; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1
Gene ID
931
UniProt ID
A0A024R507

RELATED PRODUCTS

Cat #
TAB-1639CL-F(E)
Description
Anti-Human MS4A1 Therapeutic Antibody Fab Fragment (1588)
<table>
<thead>
<tr>
<th>Product Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAB-1690CL-S(P)</td>
<td>Anti-Human MS4A1 Therapeutic Antibody scFv Fragment (Rituximab)</td>
</tr>
<tr>
<td>TAB-1668CL</td>
<td>Anti-Human MS4A1 Therapeutic Antibody (c1K1736)</td>
</tr>
<tr>
<td>TAB-1649CL-S(P)</td>
<td>Anti-Human MS4A1 Therapeutic Antibody scFv Fragment (BLX-301)</td>
</tr>
<tr>
<td>TAB-1674CL-F(E)</td>
<td>Anti-Human MS4A1 Therapeutic Antibody Fab Fragment (101)</td>
</tr>
<tr>
<td>Gly-158LC</td>
<td>Recombinant Anti-Human MS4A1 Antibody (Fc glycosylation/Non fucosylated)</td>
</tr>
<tr>
<td>TAB-1682CL-F(E)</td>
<td>Anti-Human MS4A1 Therapeutic Antibody Fab Fragment (H8L15)</td>
</tr>
<tr>
<td>TAB-1695CL</td>
<td>Anti-Human MS4A1 Therapeutic Antibody (1534)</td>
</tr>
</tbody>
</table>

For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.